An observational study in Single Seizure and Epilepsy, sponsored by Dr. Gavin Winston. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-17.
Sponsored by Dr. Gavin Winston · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Seizures with a site in Canada — 9 open to participants now, 12 under way, 7 of them phase 3. Seizures · Canada.
Among the 61 studies in Seizures with a site in Canada, this one is the 4th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2023, is one of 11 observational ones, reaches primary completion later than 2 of the 11 other live ones, and was the 50th registered.
766 studies on the registry are indexed under Seizures; 133 are open to participants now.
Browse Seizures studies →9 of the 61 studies in Seizures with a site in Canada are open now. Recruiting first, the newest first:
Aeovian Pharmaceuticals, Inc. · Sites in Canada
Ages 12+
University of Alberta · Sites in Canada, United States
Ages 18–85
Epygenix · Sites in Canada, United States, Argentina and 8 more countries
Ages 2+
Longboard Pharmaceuticals · Sites in Canada, United States, Australia and 14 more countries
Ages 2–66
Xenon Pharmaceuticals Inc. · Sites in Canada, United States, Argentina and 22 more countries
Ages 12+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 92 Seizures studies recruiting now, 36 (39%) set no upper age limit and 43 (47%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 28 · Phase 4 6
First in 1992; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 275 is above the median of 140 across 216 observational studies indexed under Seizures.
Median enrollment 118 across the 49 interventional studies, 82 across the 11 observational. Of the 43 that completed or were terminated, 21 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 61 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr. Gavin Winston as lead sponsor.
Dr. Gavin Winston has 1 study filed under Seizures — fewer than ten, so there is no comparison to draw.
5 of the studies in Seizures with a site in Canada that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
| NCT04462770Phase 3EpygenixA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | 2027-04 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT07680322Aeovian Pharmaceuticals, Inc.Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1) | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Seizures with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
One in 10 people have a seizure during their life. Usually no cause is identified. Seizures without an identified cause are called unprovoked first seizure (UFS). Most people with UFS do not have further seizures. Being able to predict the risk of more seizures as soon as possible would help doctors decide whether to suggest treatment after UFS.
Studies show that seizures are associated with changes in brain structure and function that are difficult to detect with standard assessments but can be detected with advanced techniques. Changes in connections between brain regions are also linked to subtle problems in thinking and mood.
The investigators will examine brain connections using detailed brain scans, thinking, and mood in people with UFS and develop an accurate method for calculating the risk of further seizures.
200 adult patients and 75 matched healthy controls from the Halifax and Kingston First Seizure Clinics will undergo cognitive screening assessment of major cognitive domains, MRI imaging including structural scans, resting-state functional MRI (rsfMRI) and diffusion-weighted imaging (DWI), and EEG.
Seizure recurrence will be assessed prospectively and a multimodal machine learning model will be trained to predict seizure recurrence at 12 months.
Patients aged 18-65 years old with unprovoked first seizure; age, sex and education-matched healthy controls.
Multi-centre, the study population will consist of adults from across Atlantic Canada, and South-Eastern Ontario.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undergo cognitive screening assessment, MRI imaging and EEG (if not already done) within 2-4 weeks of the initial First seizure clinic visit. Seizure recurrence will be monitored by a diary provided to each participant with details of the research team to contact in the event of a seizure. A researcher via perform telephone reminders at 3, 6, 9 and 12 months following the seizure. The primary outcome will be seizure recurrence at 12 months.
Healthy control participants will complete the same neuropsychological battery, MRI scans and EEG protocols to evaluate baseline level of impairment in a healthy population and for the group comparisons of UFS to healthy controls to establish the changes already present at initial presentation with UFS.
Number of Participants with Seizure Recurrence after Unprovoked First Seizure
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Sep 2026, 37 months after the start.
Of 53 non-industry observational studies under Seizures, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 18. This study's planned 37 months is below that.
Counting every sponsor, half of 80 studies reached it within 37 months; a quarter within 18 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.